Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by Alpha7 nicotinic receptors and potentiated by PNU-120596.
about
Neuroinflammation and psychiatric illnessnAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Understanding the role α7 nicotinic receptors play in dopamine efflux in nucleus accumbensAxonal varicosity density as an index of local neuronal interactionsThalamic glutamate decreases with cigarette smokingThe effect of combined glutamate receptor blockade in the NTS on the hypoxic ventilatory response in awake rats differs from the effect of individual glutamate receptor blockade.Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of ratsAcetylcholine α7 nicotinic and dopamine D2 receptors are targeted to many of the same postsynaptic dendrites and astrocytes in the rodent prefrontal cortex.Androgen influence on prefrontal dopamine systems in adult male rats: localization of cognate intracellular receptors in medial prefrontal projections to the ventral tegmental area and effects of gonadectomy and hormone replacement on glutamate-stimAcute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.Nicotinic acetylcholine receptors in attention circuitry: the role of layer VI neurons of prefrontal cortex.Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature.A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia.Prefrontal neuromodulation by nicotinic receptors for cognitive processes.Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.Kynurenines and Glutamate: Multiple Links and Therapeutic Implications.Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry.Nicotinic receptors mediate stress-nicotine detrimental interplay via dopamine cells' activity.cAMP-dependent protein kinase inhibits α7 nicotinic receptor activity in layer 1 cortical interneurons through activation of D1/D5 dopamine receptors.The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex.
P2860
Q21245244-58FC8203-6FB0-4988-9277-5889D0DAF2B4Q30362464-C5EB86CC-BDBC-45C0-B590-5190EEBE5C67Q30404614-783948ED-1B98-45E7-82FC-8CB1BEF4D90FQ33980053-4258F15E-1856-4AD6-9370-A127D553F686Q34276587-6208F1C8-513D-4250-BBA2-086B33AC72F9Q34582381-70CC99C0-3982-46B2-8613-2B5051D36D5FQ35182164-12927B66-B253-4C56-97AE-D85F4D10607BQ35213516-08BD5C43-42A0-4781-ADEA-6E2744D98110Q35975080-CAC9EA35-D0D1-4E88-B1E8-97F4DDDA865EQ36407275-D73A1291-6C5E-46F8-9495-6C7640DBE8A3Q36883052-9D8E707B-5BB2-44E9-87D6-BC68463C3A89Q37629127-C7B365BE-85C1-4490-9AC2-89BB22F99F03Q37651602-EDF22A08-8B30-4EEB-AE7D-89D9E3D5EEEDQ37962995-12CC1FB1-7F9B-487B-B0FA-EBE6A50183E8Q37976289-7D230F29-192D-4A2F-A0AC-A4F070DD9DC5Q38253573-EC9450F1-FDA6-4BFB-816C-BD15878A60AEQ38286246-62341B39-FC1A-46A6-AD8E-A07407AB365EQ38861843-3050B30A-7573-4411-AF48-88BAB8B609A6Q42554387-0FDFD880-38A0-475E-AB9D-E2203B43859DQ47607434-23D31E97-29F2-4BF9-BAFD-C2C75B5E0151Q48169260-E57E6CDA-6D61-4FAB-9D93-6DC6E0B9930AQ48785714-7F1AAEF8-5FC1-4055-8931-F69008EDF7ABQ50331698-254D29C6-F56F-44F0-8148-7D18D7FBF7E5
P2860
Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by Alpha7 nicotinic receptors and potentiated by PNU-120596.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Glutamate-dopamine crosstalk i ...... and potentiated by PNU-120596.
@ast
Glutamate-dopamine crosstalk i ...... and potentiated by PNU-120596.
@en
Glutamate-dopamine crosstalk i ...... and potentiated by PNU-120596.
@nl
type
label
Glutamate-dopamine crosstalk i ...... and potentiated by PNU-120596.
@ast
Glutamate-dopamine crosstalk i ...... and potentiated by PNU-120596.
@en
Glutamate-dopamine crosstalk i ...... and potentiated by PNU-120596.
@nl
prefLabel
Glutamate-dopamine crosstalk i ...... and potentiated by PNU-120596.
@ast
Glutamate-dopamine crosstalk i ...... and potentiated by PNU-120596.
@en
Glutamate-dopamine crosstalk i ...... and potentiated by PNU-120596.
@nl
P2093
P1476
Glutamate-dopamine crosstalk i ...... and potentiated by PNU-120596.
@en
P2093
James N C Kew
Jane A Dickinson
Jayaraman Srinivasan
Phil D Livingstone
Susan Wonnacott
P2888
P304
P356
10.1007/S12031-009-9232-5
P577
2009-08-18T00:00:00Z
P6179
1029095138